REG - Medpal AI PLC - NHS Approval & Operational Update

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nRSJ8403Ga&default-theme=true

RNS Number : 8403G  Medpal AI PLC  10 November 2025

10 November 2025

MedPal AI plc

("MedPal AI" or the "Company")

NHS Contract Approval

Operational Update

 

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company focused on health and wellness management, is pleased to
announce that its wholly owned subsidiary, MedPal Limited, has received formal
approval from Norfolk and Waveney Integrated Care Board ("ICB") for the change
of ownership of the NHS Pharmacy Contract previously held by Universal
Pharmacy Limited (in administration) ("Universal"). This formally completes
the acquisition of the assets from Universal as announced by the Company on 1
October 2025 - Link
(https://irtools.co.uk/90/story/fb8c58e5-a153-41f7-80f4-4dd0754be33a) .

The Company is also pleased to provide an operational update for the period
since its admission to trading on AIM on 26 August 2025.

NHS Contract Approval

On 4 November 2025, Norfolk and Waveney ICB approved the change of ownership
application, marking the official transfer of Universal's NHS Distance Selling
Pharmacy ("DSP") contract to MedPal Limited. This represents MedPal AI's first
NHS contract and enables MedPal Limited to provide regulated NHS
pharmaceutical services nationwide. The General Pharmaceutical Council
("GPhC") ceased issuing new DSP licences in June 2025, making this acquisition
particularly significant.

Operational Update

MedPal AI app

The Company continues to develop its AI-driven wellness app, which aggregates
data from over 100 wearables and health apps to provide personalised lifestyle
guidance. The launch of MedPal.clinic completes the Company's dual-engine
business model, creating a highly complementary flywheel that drives demand
generation through the wellness app whilst fulfilling clinical needs through
MedPal.clinic's regulated pharmacy services. This integrated approach combines
AI-driven wellness insights with seamless access to prescription medications,
positioning the Company uniquely in the digital healthcare market.

MedPal.clinic

Since the Company's announcement of the Acquisition on 1 October 2025, Medpal
Limited dispensed 14,757 prescriptions, each written at least at the current
NHS prescription charge of £9.90 per item. This strong initial performance
demonstrates significant early demand for the Company's automated pharmacy
services and validates its investment in advanced robotic dispensing
technology.

The Company has also already received orders for weight loss drugs through its
newly launched weight loss service at MedPal.clinic, which was announced on 7
November 2025. This early uptake is beyond the Board's expectations and
reflects growing consumer demand for accessible telehealth services combined
with rapid medication fulfilment.

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"We are delighted to announce the formal approval of our NHS contract from
Norfolk and Waveney ICB. This milestone marks MedPal Limited's official entry
into NHS pharmaceutical services and represents a significant validation of
our operational capabilities.

"The strong trading performance since opening our distribution centre has
exceeded our initial expectations, with nearly 15,000 prescription items
dispensed in the 10 days of operation. This early momentum, combined with
encouraging uptake of our private weight loss service, demonstrates the market
appetite for our AI-enhanced, automated pharmacy model.

"We remain focused on scaling our operations efficiently whilst maintaining
the highest standards of patient safety and service quality. The combination
of our NHS contract, state-of-the-art automated dispensing capabilities, and
growing private telehealth services positions us well for sustainable growth
in the rapidly evolving digital healthcare market.

"The traditional pharmacy model is failing many users on cost, convenience,
and accessibility. MedPal AI has built an integrated, AI-powered healthcare
ecosystem that operates 24/7, making healthcare easily accessible and more
affordable for everyone."

Listen to CEO Jason Drummond discuss the formal approval via the following
link:
https://www.voxmarkets.co.uk/articles/q-a-with-medpal-ai-ceo-jason-drummond-d9d2880
(https://www.voxmarkets.co.uk/articles/q-a-with-medpal-ai-ceo-jason-drummond-d9d2880)

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company take
responsibility for the contents of this announcement.

 

Enquiries:

 MedPal AI plc                                   Via Square1 Consulting

 Jason Drummond, Chief Executive Officer
 Cairn Financial Advisers LLP                    +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited                   +44 (0) 20 3869 6080

 Bob Roberts/ Nick Josh

 Square1 Consulting                              +44 (0) 20 7929 5599

 David Bick                                      +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

This information is provided by RNS, the news service of the London Stock
Exchange. RNS is approved by the Financial Conduct Authority to act as a
Primary Information Provider in the United Kingdom. Terms and conditions
relating to the use and distribution of this information may apply. For
further information, please contact rns@lseg.com or visit www.rns.com
(www.rns.com) .

RNS may use your IP address to confirm compliance with the terms and
conditions, to analyse how you engage with the information contained in this
communication, and to share such analysis on an anonymised basis with others
as part of our commercial services. For further information about how RNS and
the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDGBDBRBGDGUC



            Copyright 2019 Regulatory News Service, all rights reserved